Artelo Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies aimed at modulating the endocannabinoid system, recently incurred an income tax expense of -$209,000.00 indicating its tax obligations. In assessing its operational efficiency, the gross profit ratio stands at 0.00 which reflects the effectiveness of the company's production and sales efforts. With operating expenses totaling $10,287,000.00 the company has accounted for the various costs associated with its operations. Artelo also reported an income before tax of -$10,083,000.00 showcasing its pre-tax profitability, while the gross profit reached $0.00 highlighting the company's profitability derived from its core activities. The product candidate pipeline includes promising developments such as ART27.13, a synthetic G protein-coupled receptor agonist in Phase 1b/2a clinical trials for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal aimed at addressing inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for the treatment of prostate and breast cancer, as well as PTSD. Collaborating with Trinity College Dublin, Artelo is investigating ART27.13 specifically for cancer cachexia, demonstrating its commitment to addressing unmet medical needs. Founded in 2011 and originally named Reactive Medical, Inc., the company rebranded to Artelo Biosciences, Inc. in April 2017 and is headquartered in Solana Beach, California. In terms of financial accessibility, the stock is affordable at $9.50 making it suitable for budget-conscious investors. However, it has a low average trading volume of 533,554.00 indicating lower market activity. With a market capitalization of $5,740,004.00 Artelo is classified as a small-cap player within the biopharmaceutical sector. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall landscape of healthcare innovation. Positioned in the Healthcare sector, Artelo Biosciences, Inc. drives innovation and growth, reflecting its strategic focus on developing therapeutic solutions that leverage the endocannabinoid system for various medical applications.